Standout Papers

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in ... 2005 2026 2012 2019 1.1k
  1. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. (2005)
    Michel Marty, Francesco Cognetti et al. IRIS UNIMORE (University of Modena and Reggio Emilia)

Immediate Impact

4 by Nobel laureates 11 from Science/Nature 78 standout
Sub-graph 1 of 17

Citing Papers

Natural killer cell therapies
2024 StandoutNature
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
2022 Standout
1 intermediate paper

Works of Carol Ward being referenced

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
2005 Standout
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
2005

Author Peers

Author Last Decade Papers Cites
Carol Ward 77 1132 119 509 300 14 1.4k
Rebecca Moroose 30 719 68 214 185 22 1000
Domenico Magazzù 117 882 52 308 554 18 1.3k
Thinh Q. Pham 105 905 58 406 180 10 1.3k
RD Rubens 115 1312 19 565 256 16 1.7k
Richard A. Michaelson 39 814 58 382 123 18 1.0k
David Peston 153 718 52 192 276 26 1.5k
O.O. Melnyk 151 739 119 305 322 26 1.6k
Magdalena Koziczak 41 692 82 378 307 9 1.4k
N. Al-Sakaff 57 868 40 330 311 27 1.1k
Catherine A. Azar 161 863 57 143 356 13 1.1k

All Works

Loading papers...

Rankless by CCL
2026